BRINGING THE BENCH 

TO THE BEDSIDE.

ProBio ('Prostate Biomarkers') is an adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven phase 3 trial in men with CRPC. Men (n=750) will be randomized to receive either standard of care (following national guidelines) or treatment with Enzalutamide, Abiraterone, Docetaxel, Cabazitaxel, or Carboplatin, based on a liquid biopsy profile.